Ovid Therapeutics Inc.
NASDAQ Global SelectRecent
price
P/E
ratio
div
yld
- -
ROIC.AI
Capital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- Similar Companies
- Business
- Ovid Therapeutics Inc. (NASDAQ: OVID), a New York-based biopharmaceutical company founded in 2014 and headquartered at 441 Ninth Avenue, 14th Floor, New York, NY, develops small-molecule medicines targeting epilepsies, seizure-related disorders, and other central nervous system (CNS) conditions with significant unmet needs in the United States and globally. The company's pipeline features OV329, a next-generation GABA-aminotransferase inhibitor advancing in Phase 1 trials for treatment-resistant seizures and undisclosed indications, offering potent synaptic and extrasynaptic inhibition with reduced sedation and no ocular risks associated with vigabatrin; OV350, the lead from its KCC2 direct activator library, demonstrating preclinical antipsychotic and anticonvulsant effects for potential Phase 1 initiation in early 2025 targeting psychosis in neuronal-synuclein diseases like Parkinson's and Lewy body dementia; OV4071 and additional KCC2 compounds for neuropsychiatric, neurodevelopmental, and neurodegenerative disorders, suitable for oral and intramuscular formulations; and a broader KCC2 portfolio addressing neuronal hyperexcitability across multiple CNS applications. Recent developments include a June 2025 agreement with Immedica Pharma AB to sell worldwide ganaxolone royalty rights and intellectual property for $7.0 million, providing non-dilutive capital to extend runway into early 2026 and refocus on wholly owned assets without impacting the core pipeline; topline Phase 1 data readout for OV329 expected in Q3 2025 from an expanded higher-dose cohort; a private placement priced in October 2025 raising approximately $81 million initially to fund operations and clinical programs into 2028; leadership enhancements with board addition of Dr. Stelios Papadopoulos and hires of Dr. Manal Morsy and Victoria Fort; and prior collaborations such as with Gensaic for up to three gene therapies and licensing from AstraZeneca and Tufts University to bolster CNS candidates.
Ovid Therapeutics Strengthens Executive Leadership Team to Support Continued Pipeline Progress and Next Phase of Development
Ovid Therapeutics: Risk-Adjusted Valuation Shows Deep Discount Despite 700% Rally
Ovid Therapeutics: Buy Next-Gen GABA-Aminotransferase Inhibitor OV329 And TSC/IS Expansions
Ovid Therapeutics to Participate in Upcoming Investor Conferences
Ovid Therapeutics Appoints Leading Physician-Scientist and Biotech Innovator Anna Greka, M.D., Ph.D., to Board of Directors
Ovid Therapeutics Reports Business Updates and First Quarter 2026 Financial Results
AtaiBeckley wins OVID Health Silver Award for patient partnership in psychedelic trials
Ovid Therapeutics Inc. (OVID) Discusses KCC2 Deep Dive and Pipeline Advances in CNS Disorders Transcript
Ovid Therapeutics to Host Potassium-Chloride Co-transporter 2 (KCC2) Deep Dive R&D Event on Tuesday, April 14
Ovid Therapeutics (NASDAQ:OVID) Receives Consensus Recommendation of “Buy” from Brokerages
Ovid Therapeutics: Seizing The Moment With Phase 2 Ready Assets And PIPE Funding
Ovid Therapeutics Inc. (OVID) Q4 2025 Earnings Call Transcript
Here's Why Ovid Therapeutics Stock Popped Higher Today
Ovid Therapeutics' New Epilepsy Trial Data Ignites Rally
Ovid Therapeutics (OVID) Q4 Earnings and Revenues Surpass Estimates
Ovid Therapeutics Announces New OV329 Data and Indication Expansion, Phase 1 Clearance for OV4071, and Reports Fourth Quarter and Full Year 2025 Financial Results
Ovid Therapeutics Announces Pricing of $60 Million Private Placement
Ovid Therapeutics to Participate in Upcoming Investor Conferences
Ovid Therapeutics: Bullish Post-PIPE With 2 Differentiated CNS Moonshots
Ovid Therapeutics (NASDAQ:OVID) Receives Consensus Recommendation of “Buy” from Analysts